Dynorphin-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat.
Intracerebroventricular administration of dynorphin-(1-13) inhibits dose-dependently plasma vasopressin level in normal as well as in water-deprived rats, whereas systemic (subcutaneous) administration of this opioid peptide is ineffective in this respect. Simultaneous subcutaneous, but not intracerebroventricular, administration of naloxone prevents the suppressive effect of dynorphin-(1-13) on plasma vasopressin levels.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004399:Dynorphins / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012965:Sodium Chloride / Q000008:administration & dosage; D014667:Vasopressins / Q000097:blood*; D014868:Water Deprivation / Q000502:physiology
D010446:Peptide Fragments; D014667:Vasopressins; D012965:Sodium Chloride; C026843:dynorphin (1-13); D004399:Dynorphins